Ravi Chari
PhD
Chief Scientific Officer
👥Biography 个人简介
Ravi Chari is a veteran ADC scientist who developed mirvetuximab soravtansine, the first ADC approved for folate receptor alpha-positive ovarian cancer. His continued work on next-generation maytansinoid payloads has pushed the boundaries of ADC potency and selectivity. He has been instrumental in expanding the ADC payload toolkit beyond traditional cytotoxic mechanisms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ravi Chari 的研究动态
Follow Ravi Chari's research updates
留下邮箱，当我们发布与 Ravi Chari（ImmunoGen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment